Rachael Mann1, Alesia Sadosky2, Caroline Schaefer3, Rebecca Baik3, Bruce Parsons4, Edward Nieshoff5, Brett R Stacey6, Michael Tuchman7, Srinivas Nalamachu8. 1. Covance Market Access Services Inc, San Diego, CA, USA. 2. Pfizer Inc, New York, NY, USA alesia.sadosky@pfizer.com. 3. Covance Market Access Services Inc, Gaithersburg, MD, USA. 4. Pfizer Inc, New York, NY, USA. 5. Rehabilitation Institute of Michigan/Wayne State University, Detroit, MI, USA. 6. Oregon Health & Science University, Portland, OR, USA. 7. Palm Beach Neurological Center, Palm Beach Gardens, FL, USA. 8. International Clinical Research Institute, Overland Park, KS, USA.
Abstract
BACKGROUND: HIV-related neuropathic pain (HIV-NeP) is common; however, the burden of HIV-NeP is not well-understood. METHODS: The cross-sectional study aimed to characterize the HIV-NeP burden. A total of 103 patients with HIV-NeP recruited during routine office visits completed a questionnaire to assess patient-reported outcomes, including pain severity, health status, sleep, mood, and lost productivity. Physicians completed a 6-month retrospective chart review. RESULTS: The sample was predominantly male and not employed for pay. A majority (75.7%) of patients experienced moderate or severe pain. Pain interference, general health, physical health, and depression were worse among patients with more severe pain (all Ps < .006). Most (87.4%) patients were prescribed at least 1 medication for NeP. HIV-related neuropathic pain was associated with 36.1% work impairment. Adjusted annualized costs increased with increasing pain severity (P < .0001). CONCLUSION: The impact of HIV-NeP on health status, physical function, and depression increases with severity, resulting in substantial clinical and economic burden.
BACKGROUND:HIV-related neuropathic pain (HIV-NeP) is common; however, the burden of HIV-NeP is not well-understood. METHODS: The cross-sectional study aimed to characterize the HIV-NeP burden. A total of 103 patients with HIV-NeP recruited during routine office visits completed a questionnaire to assess patient-reported outcomes, including pain severity, health status, sleep, mood, and lost productivity. Physicians completed a 6-month retrospective chart review. RESULTS: The sample was predominantly male and not employed for pay. A majority (75.7%) of patients experienced moderate or severe pain. Pain interference, general health, physical health, and depression were worse among patients with more severe pain (all Ps < .006). Most (87.4%) patients were prescribed at least 1 medication for NeP. HIV-related neuropathic pain was associated with 36.1% work impairment. Adjusted annualized costs increased with increasing pain severity (P < .0001). CONCLUSION: The impact of HIV-NeP on health status, physical function, and depression increases with severity, resulting in substantial clinical and economic burden.
Authors: Lisa M Mangus; Rachel L Weinberg; Audrey C Knight; Suzanne E Queen; Robert J Adams; Joseph L Mankowski Journal: J Neuropathol Exp Neurol Date: 2019-01-01 Impact factor: 3.685
Authors: Marco D DiBonaventura; Alesia Sadosky; Kristen Concialdi; Markay Hopps; Ian Kudel; Bruce Parsons; Joseph C Cappelleri; Patrick Hlavacek; Andrea H Alexander; Brett R Stacey; John D Markman; John T Farrar Journal: J Pain Res Date: 2017-11-01 Impact factor: 3.133
Authors: Whitney Scott; Chinar Arkuter; Kitty Kioskli; Harriet Kemp; Lance M McCracken; Andrew S C Rice; Amanda C de C Williams Journal: Pain Date: 2018-12 Impact factor: 6.961
Authors: Ian Kudel; Markay Hopps; Joseph C Cappelleri; Alesia Sadosky; Kristen King-Concialdi; Ryan Liebert; Bruce Parsons; Patrick Hlavacek; Andrea H Alexander; Marco D DiBonaventura; John D Markman; John T Farrar; Brett R Stacey Journal: J Pain Res Date: 2019-01-07 Impact factor: 3.133
Authors: Margarita Udall; Ian Kudel; Joseph C Cappelleri; Alesia Sadosky; Kristen King-Concialdi; Bruce Parsons; Patrick Hlavacek; Markay Hopps; P Arline Salomon; Marco D DiBonaventura; Patricia Clark; João Batista Santos Garcia Journal: J Pain Res Date: 2019-01-07 Impact factor: 3.133